#USA #New York #Class Action #ARS Pharmaceuticals #SPRY

Class Action Lawsuit Filed Against ARS Pharmaceuticals

Date: August 19, 2026

In recent news, Levi & Korsinsky, LLP announced the filing of a class action lawsuit on behalf of investors affected by the significant stock price drop of ARS Pharmaceuticals Inc. (NASDAQ: SPRY). The lawsuit has been initiated following alarming disclosures about the company’s coverage decisions, leading to a substantial $250 million loss in market value in a single day.

Background of the Lawsuit

The class action revolves around allegations that ARS Pharmaceuticals misrepresented the timeline for expanded coverage of their epinephrine nasal spray, Neffy, through CVS Caremark. The expectation was set for prior-authorization-free coverage starting July 1, 2026, which the company suggested would benefit them during the crucial summer and back-to-school allergy seasons. However, the reality proved to be much different. On June 24, 2026, the company disclosed that no such decisions had been made yet, revealing that CVS Caremark's decision could potentially delay until January 2027. This unexpected announcement resulted in a swift 23.9% decline in stock price, dropping from $10.54 to $8.02 per share.

Implications for Investors

For institutional investors, such as pension funds and asset managers holding shares during the class period from March 9, 2026, to June 24, 2026, participation in this class action may be a critical avenue for seeking compensation. The lawsuit claims that many investors accumulated ARS shares based on misleading information, thus suffering quantifiable losses when the stock declined sharply.

The court has set a deadline for potential lead plaintiffs to file by October 5, 2026, giving investors a limited window to seek representation based on their financial interests. Notably, lead plaintiffs are chosen based on the size of their documented losses and their ability to adequately represent the interest of the class.

Importance of Institutional Participation

Joseph E. Levi, an attorney at Levi & Korsinsky, emphasizes the vital role institutional investors play in such securities class actions. According to Levi, their involvement not only aids in enhancing oversight of the litigation process but also signals a unified front against misrepresentation by the companies they invest in.

What Should Investors Do?

Investors who purchased SPRY shares during the class period and have experienced losses are encouraged to contact Levi & Korsinsky for a comprehensive loss assessment. They may not only be eligible to recover damages but can also play a pivotal role in shaping the litigation strategy as lead plaintiffs.

It's worth noting that those who sold SPRY shares before the lawsuit may still qualify to join the class if they purchased during the specified period. Moreover, participation in such securities class actions usually incurs no upfront costs, as they are conducted on a contingency basis.

Conclusion

As ARS Pharmaceuticals addresses its legal challenges, concerned investors remain proactive about their rights and potential recoveries. This case highlights the necessity of transparency and accountability in corporate governance—principles that protect shareholders and ensure market integrity. For any institutional investors or individuals who feel wronged by ARS Pharmaceuticals, now is the time to act, assess potential losses, and consider joining this important class action lawsuit.

For more information on how to join the class action, contact Levi & Korsinsky at (212) 363-7500 or visit their website for further guidance on the enrollment process.